- Bio-Techne’s adjusted EPS for Q4 is 49c, matching the estimate of 49c, but down from 55c last year.
- Net sales stand at $306.1 million, showing a +1.6% increase year-over-year (y/y), slightly missing the estimate of $307.1 million.
- Protein Sciences net sales are $214.0 million, a -4% decline y/y and below the $217.5 million estimate.
- Diagnostics & Genomics net sales rose sharply by +15% y/y, reaching $90.7 million, surpassing the $89.1 million estimate.
- Intersegment revenue is -$0.63 million, indicating a +12% y/y increase, but falling short of the -$0.52 million estimate.
- Adjusted gross margin is 71.1%, slightly lower than last year’s 71.6% and the estimate of 71.7%.
- Adjusted operating margin is 33.5%, a decrease from last year’s 37.1%, and slightly below the estimate of 33.8%.
- Management commented on the results, highlighting a focused approach on profitability which led to a 33.5% adjusted operating margin.
- Analyst ratings: 11 buys, 4 holds, and 0 sells.
Bio Techne Corp on Smartkarma
Analysts on Smartkarma, such as Baptista Research, have provided insights into Bio-Techne Corporation, a biotech company specializing in protein and cell-based research. According to Baptista Research‘s report titled “Bio-Techne Corporation: Growth in the Cell and Gene Therapy Market & Improved Positioning In Spatial Biology Market! – Major Drivers,” Bio-Techne displayed strong performance in the third quarter of 2024. The company exceeded expectations with a 2% year-over-year organic revenue growth, signaling potential expansion opportunities as biotech funding stabilizes amidst macroeconomic challenges in China.
In another report by Baptista Research titled “Bio-Techne Corporation: A Tale Of Resilience Amid Economic Challenges! – Major Drivers,” it was noted that despite facing challenging macroeconomic conditions, Bio-Techne reported a 2% organic revenue decline in the second quarter of fiscal year 2024. The company’s earnings were impacted by various headwinds, including a cautious biopharma spending environment and lowered demand from OEM customers. However, Bio-Techne’s core portfolio continued to drive long-term growth potential, maintaining a 7% average growth rate over the last decade.
A look at Bio Techne Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Bio Techne Corp has a promising long-term outlook. With a Momentum score of 5, the company demonstrates strong positive price trends and investor interest, positioning it well for future growth. This high Momentum score indicates that Bio Techne Corp is experiencing significant market traction and could potentially outperform its peers in the near future. Additionally, the Growth and Resilience scores of 3 suggest that the company has strong potential for expansion and is well-equipped to navigate challenges, which bodes well for its sustainability and profitability in the long run.
Bio Techne Corp, a company that focuses on developing, manufacturing, and selling biotechnology products and clinical diagnostic controls, shows balanced performance across key Smartkarma Smart Scores. While the Value and Dividend scores are at 2, pointing to modest valuation and dividend payouts, the higher scores in Growth, Resilience, and Momentum indicate a positive outlook for the company’s future prospects. Specializing in proteins, cytokines, growth factors, immunoassays, and small molecules, Bio Techne Corp appears positioned to capitalize on market opportunities and maintain its competitive edge in the biotechnology sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
